RNAi therapy is expected to diversify drug delivery mechanisms. The global RNAi therapy report highlights ongoing clinical trials, with 151 RNAi-based drugs in clinical trials. Oncology dominates RNAi clinical trials. Since its discovery, RNA interference has become an important technology for molecular biology and functional genomics. It allows scientists to silence genes with artificial triggers and utilize the cell's machinery. Pharmaceutical companies are interested in RNAi therapeutics to fill their pipelines, as existing products are exhausting, and to target currently "undruggable" diseases. Investing early in RNAi will position companies strongly in the future market for these drugs.